Sagent Pharma to Launch Flumazenil Injection, USP
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV Measures^SM packaging and labeling, designed to help reduce medication errors.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.